請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62885
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 牟中原(Chung-Yuan Mou) | |
dc.contributor.author | Nai-Tzu Chen | en |
dc.contributor.author | 陳乃慈 | zh_TW |
dc.date.accessioned | 2021-06-16T16:13:40Z | - |
dc.date.available | 2018-03-15 | |
dc.date.copyright | 2013-03-15 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-02-07 | |
dc.identifier.citation | Chapter 1:
1. Kresge, C. T.; Leonowicz, M. E.; Roth, W. J.; Vartuli, J. C. and Beck, J. S. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature, 1992, 359, 710-712. 2. Beck, J. S.; Vartuli, J. C.; Roth, W. J.; Leonowicz, M. E.; Kresge, C. T.; Schmitt, K. D.; Chu, C. T-W.; Olson, D. H.; Sheppard, E. W.; McCullen, S. B.; Higgins, J. B.; and Schlenkert, J. L. A New Family of Mesoporous Molecular Sieves Prepared with Liquid Crystal Templates. American Chemical Society. 1992, 114, 10834-10843. 3. Lee, C. H; Cheng, S. H.; Huang, I. P.; Souris, J. S.; Yang, C. S.; Mou, C. Y.; Lo, L.W., Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics, Angew Chem Int Ed Engl. 2010 , 49 (44), 8214-8219. 4. Trewyn, B. G.; Slowing, I.I.; Giri, S.; Chen, H.T.; Lin, V. S.Y. Synthesis and Functionalization of a Mesoporous Silica Nanoparticle Based on the Sol–Gel Process and Applications in Controlled Release. Accounts of Chemical Research 2007, 40 (9), 846–853. 5. Xu, C. Y.; Tang, R. L.; Hua, Y. X.; Zhang, P. X. Mesoporous Silica Materials Synthesized via Sol-Gel Methods Modified with Ionic Liquid and Surfactant Molecules Chin. J. Chem. Phys. 2008, 21, 596 6. Slowing, I. I.; Vivero-Escoto, J. L.; Wu C. W.; Lin, V. S. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008, 60(11), 1278-88 7. Hoffmann, F.; Cornelius, M.; Morell, J. R.; Froba, M. Silica-Based Mesoporous Organic–Inorganic Hybrid Materials. Angew. Chem. Int. Ed. 2006, 45, 3216-3251 8. Huh, S.; Wiench, J. W.; Yoo, J. C.; Pruski, M.; Lin, V. S. Organic Functionalization and Morphology Control of Mesoporous Silicas via a Co-Condensation Synthesis Method. Chem. Mater., 2003, 15 (22), 4247-4256 9. Souris, J. S.; Lee, C. H.; Cheng, S. H.; Chen, C. T.; Yang, C. S.;. Ho, J. A.; Mou, C. Y.; Lo, L. W. Surface Charge-Mediated Rapid Hepatobiliary Excretion of Mesoporous Silica Nanoparticles. Biomaterials, 2010, 31, 5564−5574. 10. Cheng, S. H.; Li, F. C.; Souris, J. S.; Yang, C. S.; Tseng, F. G.; Lee, H. S.; Chen, C. T.; Dong, C.Y .; Lo, L. W. Visualizing Dynamics of Sub-Hepatic Distribution of Nanoparticles Using Intravital Multiphoton Fluorescence Microscopy ACS Nano, 2012, 6, 4122−4131. 11. Cheng, S. H.; Lee, C. H.; Chen, M. C.; Souris, J. S.; Tseng, F. G.; Yang, C. S.; Mou, C. Y.; Chen, C. T.; Lo, L. W. Tri-functionalization of mesoporous silica nanoparticles for comprehensive cancer theranostics—the trio of imaging, targeting and therapy. J. Mater. Chem. 2010, 20, 6149–6157. 12. Pan, L.; He, Q.; Liu, J.; Chen, Y.; Ma, M.; Zhang, L.; Shi, J. Nuclear-Targeted Drug Delivery of TAT Peptide-Conjugated Monodisperse Mesoporous Silica Nanoparticles J. Am. Chem. Soc., 2012, 134 (13), 5722–5725. 13. H. Meng, M. Xue, T. Xia, Z. Ji, D. Tarn, J. I. Zink and A. E. Nel, Co-delivery of Doxorubicin and Bcl-2 siRNA by Mesoporous Silica Nanoparticles Enhances the Efficacy of Chemotherapy in Multidrug Resistant Cancer Cells. ACS Nano, 2011, 5, 4131–4144. 14. Cheng, S. H.; Hsieh, C. C.; Chen, N. T.; Chu, C. H.; Huang, C. M.; Chou, P. T.; Tseng, F. G.; Yang, C. S.; Mou, C. Y.; Lo, L. W. Well-defined mesoporous nanostructure modulates three-dimensional interface energy transfer for two-photon activated photodynamic therapy. 2011, Nano today, 6(6), 552-563. 15. Gary-Bobo1, M.; Mir, Y.; Rouxel, C; Brevet, D.; Basile, I.; Maynadier, M. Vaillant, O.; Mongin, O.;Blanchard-Desce, M.; Morère, A.; Garcia, M.; Durand, J. O.; Raehm, L. Mannose-Functionalized Mesoporous Silica Nanoparticles for Efficient Two-Photon Photodynamic Therapy of Solid Tumors Angew. Chem. Int. Ed. 2011, 50, 11425–11429. 16. Lee, J. E.; Lee, N. Kim, T.; Kim, J.; Hyeon, T. Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. Acc. Chem. Res., 2011, 44, 893–902. 17. Li, Z.; Barnes, J. C.; Bosoy, A.; Stoddart, J. F.; Zink, J. I. Mesoporous silica nanoparticles in biomedical applicationsw.Chem. Soc. Rev., 2012, 41, 2590–2605. 18. Mamaeva, V.; Sahlgren, C.; Linden, M. Mesoporous silica nanoparticles in medicine—Recent advances. Adv. Drug Deliv. Rev. 2012, 12, 00248-7. 19. He, Q; Shi, J. Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, J. Mater. Chem., 2011, 21, 5845 20. Vivero-Escoto,J. L.; Slowing, I. I.; Trewyn, B.G.; Lin, V. S.-Y. Mesoporous Silica Nanoparticles for Intracellular Controlled Drug Delivery. Small 2010, 6, 1952−1967. 21. Asefa, T.; Tao, Z. Biocompatibility of Mesoporous Silica Nanoparticles. Chem. Res. Toxicol 2012, 25(11):2265-84. 22. Huang, X.; Li, L.; Liu, T.; Hao, N.; Liu, H.; Chen, D.; Tang, F. The Shape Effect of Mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS. Nano 2011, 5, 5390–5399. 23. Mamaeva, V.; Rosenholm, J. M.; El Bate-Eya, L., Bergman, L.; Peuhu, E., Duchanoy, A.; Fortelius, L.E.; Landor, S.; Toivola, D..M.; Linden, M.; and Sahlgren, C. Mesoporous Silica Nanoparticles as Drug Delivery Systems for Targeted Inhibition of Notch Signaling in Cancer. Mol. Ther. 2011, 19,1538–1546. 24. He Q.; Zhang Z.; Gao F.; Li Y., Shi J. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small. 2011, 7(2):271-80. 25. Jokerst, J. V.; Lobovkina, T.; Zare, R. N.; Gambhir, S. S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 2011, 6(4), 715-728. 26. Tsai, C.P.; Chen, C.Y.; Hung, Y.; Chang F.H.; Mou, C.Y. Monoclonal antibody-functionalized mesoporous silica nanoparticles (MSN) for selective targeting breast cancer cells. J. Mater. Chem., 2009, 19, 5737–5743. 27. Wang, L. S.,; Wu, L. C.; Lu, S. Y.; Chang, L. L.; Teng, I. T.;Yang, C. M. and Ho, J. A. Biofunctionalized phospholipid-capped mesoporous silica nanoshuttles for targeted drug delivery: improved water suspensibility and decreased nonspecific protein binding. ACS Nano 2010, 4(8), 4371-4379. 28. Varkouhi, A. K.; Scholte, M.; Storm, G.; Haisma, H. J. Endosomal escape pathways for delivery of biologicals. J Control Release 2011, 151(3), 220-228. 29. Neu, M.; Fischer, D.; Kissel, T. Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J Gene Med 2005, 7(8), 992-1009. 30. Rosenholm, J. M.; Meinander, A.; Peuhu, E.; Niemi, R.; Eriksson, J. E.; Sahlgren, C.; Linden, M. Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano 2009, 3(1), 197-206. 31. Meng, H.; Liong, M.; Xia, T.; Li, Z.; Ji, Z.; Zink, J. I.; Nel, A. E. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4(8), 4539-4550. 32. Wu, C.; Chen, C.; Lai, J.; Chen, J.; Mu, X.; Zheng, J.; Zhao, Y. Molecule-scale controlled-release system based on light-responsive silica nanoparticles. Chem Commun (Camb) 2008, 23, 2662-2664. 33. Lai, J.; Mu, X.; Xu, Y.; Wu, X.; Wu, C.; Li, C.; Chen, J.; Zhao, Y. Light-responsive nanogated ensemble based on polymer grafted mesoporous silica hybrid nanoparticles. Chem Commun (Camb) 2010, 46(39), 7370-7372. 34. Baeza, A.; Guisasola, E.; Ruiz-Hernández, E.; Vallet-Regí, M. Magnetically Triggered Multidrug Release by Hybrid Mesoporous Silica Nanoparticles Silica Nanoparticles. Chem. Mater. 2012, 24, 517-524. 35. Chen, L. C.; Wei, C. W.; Souris, J. S.; Cheng, S. H.; Chen, C. T.; Yang, C. S.; Li, P. C.;Lo, L. W. Enhanced photoacoustic stability of gold nanorods by silica matrix confinement. J Biomed Opt 2010, 15(1), 016010. 36. Li, X., Zhang, J. and Gu, H. Adsorption and desorption behaviors of DNA with magnetic mesoporous silica nanoparticles. Langmuir 2011, 27(10), 6099-6106. 37. Kim, J., Kim, H. S., Lee, N., Kim, T., Kim, H., Yu, T., Song, I. C., Moon, W. K. and Hyeon, T. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew Chem Int Ed Engl 2008, 47(44), 8438-8441. 38. Zhang, J.; Li, X.; Rosenholm, J. M.; Gu, H. C. Synthesis and characterization of pore size-tunable magnetic mesoporous silica nanoparticles. J Colloid Interface Sci 2011, 361(1), 16-24. 39. Suteewong, T.; Sai, h.; Lee, j.; Bradbury, M.; Hyeon, T.; Gruneref, S. M.; Wiesner, U. Ordered mesoporous silica nanoparticles with and without embedded iron oxide nanoparticles: structure evolution during synthesis. 2010, 20, 7807-7814. 40. Ma, M.; Chen, H.; Chen, Y.; Wang, X.; Chen, F.; Cui, X.; Shi, J. Au capped magnetic core/mesoporous silica shell nanoparticles for combined photothermo-/chemo-therapy and multimodal imaging. Biomaterials 2012, 33(3), 989-998. 41. Wu, S. H.; Lin, C. Y.; Hung, Y.; Chen, W.; Chang, C.; Mou, C. Y. PEGylated silica nanoparticles encapsulating multiple magnetite nanocrystals for high-performance microscopic magnetic resonance angiography. J Biomed Mater Res B Appl Biomater 2011, 99(1), 81-88. 42. Wu, S. H.; Lin, Y. S.; Hung, Y.; Chou, Y. H.; Hsu, Y. H.; Chang, C.; Mou, C. Y. Multifunctional mesoporous silica nanoparticles for intracellular labeling and animal magnetic resonance imaging studies. Chembiochem 2008, 9(1), 53-57. 43. Wu, S. H.; Lin, Y. S.; Hung, Y.; Chou, Y. H.; Chang C.; Mou, C. Y. Multifunctional Mesoporous Silica Nanoparticles as Dual-mode Imaging Probes. Studies in Surface Science and Catalysis 2007, 170, 1804-1810. 44. Kim, J., Kim, H. S., Lee, N., Kim, T., Kim, H., Yu, T., Song, I. C., Moon, W. K. and Hyeon, T. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew Chem Int Ed Engl 2008, 47(44), 8438-8441. 45. Lee, J. E.; Lee, D.J.; Lee, N.; Kim, B. H.; Choi, S. H.; Hyeon, T. Multifunctional mesoporous silica nanocomposite nanoparticles for pH controlled drug release and dual modal imaging. J. Mater. Chem. 2011, 21, 16869 46. Mooradian, A., Photoluminescence of Metals. Phys. Rev. Lett. 1969, 22, 185–187. 47. Boyd, G. T.; Yu, Z. H.; Shen, Y. R., Photoinduced luminescence from the noble metals and its enhancement on roughened surfaces. Phys Rev B Condens Matter 1986, 33, 7923–7936. 48. Apell, P.; Monreal, R.; Lundqvist, S., Photoluminescence of noble metals. Phys. Scr. 1988, 38, 174–179. 49. Wang, D. S.; Hsu, F. Y.; Lin, C. W. Surface plasmon effects on two photon luminescence of gold nanorods. Optical Express 2009, 19, 11350–11358. 50. Lin, A.; Son, D. H.; Ahn, I. H.; Song, G. H.; Han, W. T. Visible to infrared photoluminiscence from gold nanoparticles embedded in germano-silicate glass fiber. Optical express, 2007, 15, 6374–6379. 51. Mohamed, M. B.; Volkov, V.; Link, S.; El-Sayed, M. A. The ‘lightning’ gold nanorods: fluorescence enhancement of over a million compared to the gold metal. Chemical Physics Letters 2000, 317, 517–523 Chapter 2: 1. Xia, Y.; Li, W.; Cobley, C.M.; Chen, J.; Xia, X.; Zhang, Q.; Yang, M.; Cho, E.C.; Brown, P. K. Gold nanocages: from synthesis to theranostic applications. Accounts of Chemical Research, 2011, 44, 914–924. 2. Alkilany, A. M.; Thompson, L. B.; Boulos, S. P.; Sisco, P. N.; Murphy, C. J. Gold nanorods: Their potential for photothermal therapeutics and drug delivery, tempered by the complexity of their biological interactions. Advanced Drug Delivery Reviews 2012, 64, 190–199. 3. Liu, C. L.; Wu, H. T.; Hsiao, Y. H.; Lai, C. W.; Shih, C. W.; Peng, Y. K.; Tang, K. C.; Chang, H. W.; Chien, Y. C.; Hsiao, J. K.; et al. Insulin-directed synthesis of fluorescent gold nanoclusters: preservation of insulin bioactivity and versatility in cell imaging. Angew. Chem. Int. Edit. 2011, 50, 7056–7060. 4. Cheng, J. X.; Tong, L.; Wei, Q. S.; Wei, A., Gold nanorods as contrast agents for biological imaging: optical properties, surface conjugation and photothermal effects. Photochemistry and Photobiology 2009, 85, 21–32. 5. Qian, J.; Zhan, Q. Q.; Li, X.; He, S. L., A study of mesoporous silica-encapsulated gold nanorods as enhanced light scattering probes for cancer cell imaging. Nanotechnology 2010, 21 (5).055704–055712. 6. Kuo, W. S.; Chang, C. N.; Chang, Y. T.; Yang, M. H.; Chien, Y. H.; Chen, S. J.; Yeh, C. S., Gold nanorods in photodynamic therapy, as hyperthermia agents, and in near-infrared optical imaging. Angewandte Chemie-International Edition 2010, 49, 2711–2715. 7. Tong, L.; He, W.; Zhang, Y.; Zheng, W.; Cheng, J. X. Visualizing systemic clearance and cellular level biodistribution of gold nanorods by intrinsic two-photon luminescence. Langmuir 2009, 25(21), 12454–12459. 8. Imura, K.; Okamoto, H. Properties of photoluminescence from single gold nanorods induced by near-field two-photon excitation. J. Phys. Chem. C 2009, 113, 11756–11759. 9. Mooradian, A., Photoluminescence of Metals. Phys. Rev. Lett. 1969, 22, 185–187. 10. Apell, P.; Monreal, R.; Lundqvist, S., Photoluminescence of noble metals. Phys. Scr. 1988, 38, 174–179. 11. Boyd, G. T.; Yu, Z. H.; Shen, Y. R., Photoinduced luminescence from the noble metals and its enhancement on roughened surfaces. Phys Rev B Condens Matter 1986, 33, 7923–7936. 12. Wang, D. S.; Hsu, F. Y.; Lin, C. W. Surface plasmon effects on two photon luminescence of gold nanorods. Optical Express 2009, 19, 11350–11358. 13. Lin, A.; Son, D. H.; Ahn, I. H.; Song, G. H.; Han, W. T. Visible to infrared photoluminiscence from gold nanoparticles embedded in germano-silicate glass fiber. Optical express, 2007, 15, 6374–6379. 14. Mohamed, M. B.; Volkov, V.; Link, S.; El-Sayed, M. A., The ‘lightning’ gold nanorods: fluorescence enhancement of over a million compared to the gold metal. Chemical Physics Letters 2000, 317, 517–523 15. Yorulmaz, M.; Khatua, S.; Zijlstra, P.; Gaiduk, A.; Orrit, M. Luminescence quantum yield of single gold nanorods Nano Lett. 2012, 12, 4385−4391. 16. Eustis, S.; El-Sayed, M. A. Why gold nanoparticles are more precious than pretty gold: Noble metal surface plasmon resonance and its enhancement of the radiative and nonradiative properties of nanocrystals of different shapes. Chem. Soc. Rev., 2006, 35, 209–17 17. Durr, N. J.;Larson, T.; Smith, D. K.; Korgel, B. A.; Sokolov, K.; Ben-Yakar, A. Two-photon luminescence imaging of cancer cells using molecularly targeted gold nanorods Nano Lett., 2007, 7, 941–945. 18. Wang, H.; Huff, T. B.; Zweifel, D. A.; He, W.; Low, P. S.; Wei, A.; Cheng, J. X., In vitro and in vivo two-photon luminescence imaging of single gold nanorods. Proc Natl Acad Sci U S A 2005, 102, 15752–6. 19. Chen, C. L.; Kuo, L. R.; Chang, C. L.; Hwu, Y. K.; Huang, C. K.; Lee, S. Y.; Chen, K.; Lin, S. J.; Huang, J. D.; Chen, Y. Y., In situ real-time investigation of cancer cell photothermolysis mediated by excited gold nanorod surface plasmons. Biomaterials 2010, 31, 4104–4112. 20. Yeh, C. S.; Kuo, W. S.; Chang, C. N.; Chang, Y. T., Antimicrobial gold nanorods with dual-modality photodynamic inactivation and hyperthermia. Chemical Communications 2009, 32, 4853–4855. 21. Jang, B.; Park, J.Y.; Tung, C.H.; Kim, I.H.; Choi, Y. Gold nanorod-photosensitizer complex for near-infrared fluorescence imaging and photodynamic/photothermal therapy in vivo. ACS Nano, 2011, 5,1086–1094 22. Jang, B.; Choi, Y., Photosensitizer-conjugated gold nanorods for enzyme-activatable fluorescence imaging and photodynamic therapy. Theranostics 2012, 2, 190–7. 23. Zhao, T.; Wu, H.; Yao, S. Q.; Xu, Q. H.; Xu. G. Q. Nanocomposites containing gold nanorods and porphyrin-doped mesoporous silica with dual capability of two-photon imaging and photosensitization. Langmuir 2010, 26, 14937–14942. 24. Zhang, Z.; Wang, L.; Wang, J.; Jiang, X.; Li, X.; Hu, Z.; Ji, Y.; Wu, X.; Chen, C., Mesoporous silica-coated gold nanorods as a light-mediated multifunctional theranostic platform for cancer treatment. Adv Mater 2012, 24, 1418–23. 25. Chen, Y. S.; Frey, W.; Kim, S.; Homan, K.; Kruizinga, P.; Sokolov, K.; Emelianov, S., Enhanced thermal stability of silica-coated gold nanorods for photoacoustic imaging and image-guided therapy. Optics Express 2010, 18, 8867–8877. 26. Wu, X.; Yang, F.; Ming, T.; Xiong, R.; Wang, P.; Chen, J. Au nanorods can be used for long-term cell imaging? Appl Phys Lett, 2011, 98, 213704 27. Stephan Link; El-Sayed, M. A., Shape and size dependence of radiative, non-radiative and photothermal properties of gold nanocrystals. INT REV PHYS CHEM 2000, 19, 409–453. 28. Bouhelier, A.; Bachelot, R.; Lerondel, G.; Kostcheev, S.; Royer, P.; Wiederrecht, G. P., Surface plasmon characteristics of tunable photoluminescence in single gold nanorods. Phys Rev Lett 2005, 95, 267405–9. 29. Chen, L. C.; Wei, C. W.; Souris, J. S.; Cheng, S. H.; Chen, C. T.; Yang, C. S.; Li, P. C.; Lo, L. W., Enhanced photoacoustic stability of gold nanorods by silica matrix confinement. Journal of Biomedical Optics 2010, 15, 016010–6. 30. Wu, C.; Xu, Q. H. Stable and functionable mesoporous silica-coated gold nanorods as sensitive localized surface plasmon resonance (LSPR) nanosensors. Langmuir 2009, 25, 9441–9446 31. Chen, Y.S.; Frey, W.; Kim, S.; Kruizinga, P.; Homan, K.; Emelianov, S. Silica-coated gold nanorods as photoacoustic signal nanoamplifiers. Nano Lett. 2011, 11, 348–354 32. Nikoobakht, B.; El-Sayed, M. A., Preparation and Growth Mechanism of Gold Nanorods (NRs) Using Seed-Mediated Growth Method. Chem. Mater. 2003, 15, 1957–1962. 33. Gorelikov, I.; Matsuura, N., Single-step coating of mesoporous silica on cetyltrimethyl ammonium bromide-capped nanoparticles. Nano Lett 2008, 8, 369–73. 34. Cheng, S.H.; Lee, C.H.; Yang, C.S.; Tseng, F.G.; Mou, C.Y.; Lo, L.W., Mesoporous silica nanoparticles functionalized with an oxygen-sensing probe for cell photodynamic therapy: potential cancer theranostics J. Mater. Chem., 2009, 19, 1252–1257 35. Hoebeke M; Piette J; A., v. d. V., Photosensitized production of singlet oxygen by merocyanine 540 bound to liposomes. J Photochem Photobiol B 1991, 9 (3-4), 281–294. 36. Chung, T. H.; Wu, S. H.; Yao, M.; Lu, C. W.; Lin, Y. S.; Hung, Y.; Mou, C. Y.; Chen, Y. C.; Huang, D. M. The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. Biomaterials 2007, 28, 2959−2966. Chapter 3: 1. Jiang, X. B.; Yang, Q. Y.; Sai, K.; Zhang, X. H.; Chen, Z. P.; Mou, Y. G. Brain metastases from colorectal carcinoma: a description of 60 cases in a single Chinese cancer center, Tumor Biology, 2011,32, 6, 1249–1256, 2. Raedler, A.; Raedler, E. The use of lectins to study normal differentiation and malignant transformation. J. Cancer Res. Clin. Oncol. 1985,109, 245-251. 3. Natsume, A.; Wakitani, M.; Yamane-Ohnuki, N.; Shoji-Hosaka, E.; Niwa, R.; Uchida, K.; Satoh, M.;. Shitara, K.; Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region. J. Biochem. 2006, 140, 359-368. 4. Yuan, K.; Listinsky, C.; Singh, M. R. K.; Listinsky, J. J.; Siegal, G. P. Cell surface associated alpha-L-fucose moieties modulate human breast cancer neoplastic progression. Pathol. Oncol. Res. 2008, 14, 145-156. 5. Haltiwanger, R. S. Fucose is on the TRAIL of colon cancer. Gastroenterology. 2009, 137, 36-39. 6. Listinsky, J. J.; Siegal, G. P.; Listinsky, C. M. The emerging importance of alpha-L-fucose in human breast cancer: a review. Am. J. Transl. Res. 2011,3, 292-322. 7. Hattrup, C. L.; Gendler, S. J. Structure and function of the cell surface (tethered) mucins. Annu. Rev. Physiol. 2008, 70, 431-457. 8. Roney, C. A.; Xu, B.; Xie, J.; Yuan, S.; Wierwille, J.; Chen, C. W.; Chen, Y.; Griffiths, G. L.; Summers, R. M. Rh-I-UEA-1 polymerized liposomes target and image adenomatous polyps in the APC(Min/+) mouse using optical colonography. Mol. Imaging. 2011, 10, 305-316. 9. Kuroki, T. Lectin staining of neoplastic and normal background colorectal mucosa in nonpolyposis and polyposis patients. Dis. Colon. Rectum., 1991. 34(8), p. 679-84. 10. Yonezawa, S. Glycoconjugate with Ulex europaeus agglutinin-I-binding sites in normal mucosa, adenoma, and carcinoma of the human large bowel. J. Natl. Cancer Inst., 1982, 69(4), 777-85. 11. Yonezawa, S. Binding of Ulex europaeus agglutinin-I in polyposis coli: comparative study with solitary adenoma in the sigmoid colon and rectum. J. Natl. Cancer Inst., 1983. 71(1), 19-24. 12. Nelilma, C.; Romeiro, A. B.; Carlos, M.R.; Sant, L. M.; Lima, C.; Fraga, A.M.; Barreiro, E. J. NSAIDs revisited: Putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARg). Euro. J. of Med. Chem. 2008, 43, 1918-1925. 13. Gary A.; Piazza, A. B.; Keeton, H. N.; Tinsley, J. D., Whitt, B. D., Gary, B. M., Raj Singh, W. E.; Grizzle, R. C.; Reynolds, C. NSAIDs: Old Drugs Reveal New Anticancer Targets. Pharmaceuticals, 2010, 3, 1652-1667. 14. Murff, H. J.; Shrubsole, M. J.; Chen, Z.; Smalley, W. E.; Chen, H.; Shyr, Y.; Ness, R. M.; Zheng, W. Nonsteroidal Anti-inflammatory Drug Use and Risk of Adenomatous and Hyperplastic Polyps. Cancer Prev Res (Phila). 2011, 4, 1799-1807. 15. Miller, S. J.; Joshi, B. P.; Feng, Y;. Gaustad, A. Fearon, E. R. Wang, T. D. In vivo fluorescence-based endoscopic detection of colon dysplasia in the mouse using a novel peptide probe. PLOS ONE. 2011, 6, e17384. 16. Deniaud, D.; Julienne, K.; Gouin, S. G. Insights in the rational design of synthetic multivalent glycoconjugates as lectin ligands. Org. Biomol. Chem. 2011, 9, 966-979. 17. Bu, X. D.; Li, N.; Tian, X. Q.; Huang, P. L. Caco-2 and LS174T cell lines provide different models for studying mucin expression in colon cancer. Tissue Cell. 2011, 43, 201-206. Chapter 4: 1. Blum, R. H.; Carter, S. K. Adriamycin, a new anticancer drug with significant clinical activity. Ann. Intern. Med. 1974, 80(1), 249-259. 2. Carter, S. K. Adriamycin – thoughts for the future Cancer Chemother. Rep. 1975 63, 1877-1883. 3. GN, H. Anthracyclines in the treatment of cancer an overview. Drug 1997, 54, 1-7. 4. Li, Z. X.; Wang, T. T.; Wu, Y. T.; Xu, C. M.; Dong, M. Y. Adriamycin induces H2AX phosphorylation in human spermatozoa. Asian J Androl. 2008, 10(5), 749-757. 5. Hurley, L. H. DNA and its associated processes as targets for cancer therapy. Nature Reviews Cancer 2002, 2, 188-200. 6. Ebba U. K.; Pauline D.; Susan P. L. Doxorucicin activateds ATM-dependnet phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. The Journal of Biological Chemistry 2004, 279(51), 53272-53281. 7. Hrelia, S.; Fiorentini, D.; Maraldi, T.; Angeloni, C.; Bordoni, A. Biagi, ;P. L.; Hakim, G. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochimica et Biophysica Acta 2002, 1567, 150-156. 8. Tewey, K. M. Rowe, T. C. Yang, L. D, H. B.; Liu. L. F. Adriamycin-induced DNA damage mediate by mammalian DNA topoisomerase II. Science 1984, 226, 466-468. 9. Christine A. F.; Loren D. W.; Giovanni U.; Gijs A. M.; Jacques H. B.; Alexander R.; Andrew H. J. W. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 1990, 29, 2538-2549. 10. Ito, T.; Oshita, S.; Nakabayashi, T.; Sun, F.; Kinjo, M. Fluorescence lifetime images of green fluorescent protein in HeLa cells during TNF-alpha induced apoptosis. Photochemical & Photobiological Sciences 2009, 8, 763-767. 11. Lin, H. J.; Herman, P.; Lakowicz, J. R. Fluorescence Lifetime-Resolved pH Imaging of Living Cells. Cytometry Part A. 2003, 52A, 77-89. 12. Schneckenburger, H. Wagner, M. Weber, P. Bruns, T. Richter, V. Multi-dimensional fluorescence microscopy of living cells. J Biophotonics 2011, 4(3), 143-9. 13. Saxl, T., Khan, F.; Matthews, D. R.; Zhi, Z. L.; Rolinski, O. Fluorescence lifetime spectroscopy and imaging of nano-engineered glucose sensor microcapsules based on glucose/galactose-binding protein Biosensors and Bioelectronics 2009, 24(11), 3229-3234. 14. Murata, S. i.; Herman, P.; Lin, H. J.; Lakowicz, J. R. Fluorescence lifetime imaging of nuclear DNA: Effect of fluorescence resonance energy transfer. Cytometry Part A. 2000, 41(3), 178-185. 15. Elangovan, M.; Day, R. N.; Periasamy, A. Nanosecond fluorescence resonance energy transfer-fluorescence lifetime imaging microscopy to localize the protein interactions in a single living cell. Journal of Microscopy 2002, 205, 3-14. 16. Lleres, D. Swift, S.; Lamond, A. I. Detecting protein-protein interactions in vivo with FRET using multiphoton fluorescence lifetime imaging microscopy (FLIM). Current Protocols in Cytometry 2007, 12(10), 1-12. 17. Porter, A. G.; Janicke. R. U. Emerging roles of caspase-3 in apoptosis. Cell Death and Differentiation 1999, 6, 99-104. 18. Mah, L. J.; Osta, A. E.; Karagiannis, T. C. γH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia 2010, 24, 679-686. 19. Rogakou, E. P.; Neira, W. N.; Boon, C.; Pommier, Y.; Bonner, W. M. Initiation of DNA Fragmentation during Apoptosis Induces Phosphorylation of H2AX Histone at Serine 139. The Journal of Biological Chemistry 2000, 275, 9390-9395. 20. Rabbani, A.; Finn, R. M.; Ausio. J. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. BioEssays 2005, 27(1), 50-56. 21. C, C.; Palumbo, M. Anti-cancer activity of anthracycline antibiotics and DNA condensation. Anticancer Drug Des. 1990, 5(3), 265-271. 22. Chaires, J. B.; Dattagupta, N.; Crothers, D. M. Binding of daunomycin to calf thymus nucleosomes. Biochemistry 1983, 22, 284-292. 23. Vigushin, D. M.; Ali, S.; Pace, P. E.; Mirsaidi, N.; Ito, K. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clinical Cancer Research 2001, 7, 971-976. 24. Chimenti, F. Bizzarr, B. Maccioni, E. Secci, D. Bolasco, A. A Novel Histone Acetyltransferase Inhibitor Modulating Gcn5 Network: Cyclopentylidene-[4-(4'-chlorophenyl)thiazol-2-yl)hydrazone. J. Med. Chem 2009, 52(2), 530-536. 25. Tóth, K.F.; Knoch, T. A.; Wachsmuth, M.; Frank-Stöhr, M.; Stöhr, M.; Bacher, C.P.; Müller, G.; Rippe, K. Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin. J. Cell Science 2004, 117(18), 4277-4287. 26. Smetana, K.; Zapotocky, M.; Starkova J.; Trka, J. Effect of histone deacetylase inhibitors on the cell nucleus and nucleolus of leukemic myeloblasts in vitro - a cytochemical study. Acta Hischem. 2007, 109, 413-419. 27. Ablack, J. N. G.; Cohen, M.; Thillainadesan, G.; Fonseca, G. J.; Pelka, P.; Torchia, J.; Mymryk, J. S. (2012) Cellular GCN5 Is a Novel Regulator of Human Adenovirus E1A-Conserved Region 3 Transactivation. Journal of Virology 86(15), 8198–8209. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/62885 | - |
dc.description.abstract | 近幾十年來,中孔洞奈米矽球作為藥物載體已在生物醫學上的應用領域越來越受到重視。中孔洞奈米矽球所具有的高表面積、均一的孔洞大小、易調控的結構及高度的生物相容性,使其在癌症治療及診斷領域成為極具潛力的奈米藥物平台。中孔洞奈米矽球與其他有機及無機材料的組合,更拓展了此材料在治療診斷上的許多協同功能性和應用多樣性。本研究主要探討中孔洞奈米矽球為基底的奈米材料於醫學診斷治療上之應用,另外,也利用了螢光生命期之變化探究藥物在離開奈米載體後,於細胞內的機制和命運。以三大主題分別探討: (1) 雙光子雷射激發所造成的電漿共振能量轉移於中孔洞矽球包覆之金奈米棒於光動力療法的應用;(2) 凝集素修飾之中孔洞奈米矽球於大腸癌症的診斷;以及(3) 利用螢光生命期影像顯微系統探討doxorubicin與DNA在細胞凋亡初期之結合和機制。
主題(1): 以中孔洞矽球包覆之金奈米棒為平台,附載光敏劑-鈀紫質,藉由粒子內所造成的電漿共振能量轉移而達到雙光子活化之光動力療法。金奈米棒於雙光子激發的影像診斷及熱治療一直是許多臨床癌症研究的重要方向,然而,金奈米棒於持續的雙光子雷射激發下的不穩定性一直是研究者欲於克服的課題,本研究中使用的中孔洞矽球包覆之金奈米棒,可達到 (i) 高度穩定金奈米棒在雙光子雷射照射下的穩定度 (ii) 提升金奈米棒釋放之雙光子冷光的強度和影像生命期 (iii)提供大量的表面積可附載鈀紫質。在雙光子雷射的激發下,藉由粒子內的能量轉移,活化鈀紫質而產生單氧,藉此殺死癌細胞。此一複合性的奈米材料不僅能做為影像診斷,並利用雙光子雷射對於組織的高穿透度,拓展了光動力療法於深層組織方面的應用,將為癌症研究帶來新的契機。 主題(2): 大腸癌為國人最常罹患之三大癌症種類之一,然而,在大腸癌症的診斷中,仍缺乏有效的顯影標記。本研究以中孔洞奈米矽球為基底,於骨架內修飾螢光分子並在矽球外表面修飾凝集素,與內視鏡系統結合,作為大腸癌症診斷的螢光探針。由體外細胞結合測試及體外及體內動物試驗,均證明凝集素修飾之中孔洞奈米矽球可專一性的結合於α-L-fucose表現之細胞和動物大腸癌組織,而競爭性測試可更進一步的確定其專一性。因此,此中孔洞奈米矽球為基底的螢光探針,可做為未來大腸癌症診斷之工具。 主題(3): 為了解藥物於奈米載體中釋放後的機制,本研究利用螢光生命期影像顯微系統,動態的觀察藥物於細胞核內與DNA結合,於早期細胞凋亡發生時所造成的螢光生命期改變,所反映的微環境變化。 總結,本研究利用多功能性的中孔洞奈米材料,結合金奈米棒或修飾外表面的標靶物質,達成此奈米材料於醫學診斷治療上的應用。未來,此奈米系統於生物醫學之應用應即具潛力。 | zh_TW |
dc.description.abstract | During the last decade, mesoporous silica nanoparticles (MSNs) have garnered great interest for potential use as nanocarriers of anticancer drugs. Their unique chemical and structural properties – their tunable size and pore diameter, excellent biocompatibility, intrinsically large surface area, and topologically distinct domains that can be easily and individually functionalized – make MSNs especially well-suited to efficient conveyance of a wide variety of therapeutic payloads. When combined with other organic/inorganic nanomaterials, the resultant MSN composites demonstrate novel synergies and even greater versatility than those of their constituents.
In this dissertation we examine, in depth, the design, synthesis, and evaluation of MSNs and MSN composites as cancer nanotheranostics: nanomaterials that simultaneously serve as both diagnostic and therapeutic agents. To accomplish this task we focus on three very different nanotheranostic constructs with three very different mechanisms of action: (1) Mesoporous silica-encased gold nanorods, for two-photon activated photodynamic therapy (TPA-PDT) via plasmonic resonance energy transfer; (2) Lectin-functionalized fluorescent MSNs, for in situ diagnostic imaging of nascent colorectal cancers using confocal fluorescence endoscopy; and (3) pH-sensitive controlled-release MSNs, for real-time fluorescence lifetime imaging microscopy (FLIM) of doxorubicin-DNA intercalation dynamics during the initial activation of apoptosis. We begin with a description of the design, synthesis, and evaluation of mesoporous silica-coated gold nanorods (MS-GNRs) that incorporate photosensitizers for TPA-PDT. Enveloping gold nanorods with mesoporous silica confers a number of advantages on bare GNRs that include: (i) stabilization of the gold nanorods’ shape against thermal deformation following repeated laser pulse irradiation; (ii) enhanced two-photon luminescence intensity and nanoplatform longevity, and (iii) increased surface area for conjugation of additional photosensitizers. Using a 2-step sequential intra-particle plasmonic energy transfer post two-photon excitation, we observe substantial cytotoxicity both in vitro and in vivo, using human breast carcinoma cells and a murine model of human breast cancer. Next we discuss our development and evaluation of MSNs that target dysplastic adenomas and whose silica frameworks contain the fluorophore fluorescein isothiocyanate (FITC), for potential use as endoscopic contrast agents of nascent colon cancer. The exteriors of these fluorescent MSNs were labeled with the lectin Ulex europaeus agglutinin 1 (UEA-1), to target the α-L-fucose that is expressed on the luminal surfaces of glycoproteins of colorectal dysplastic adenomas and nascent cancers. In vitro affinity assays, as well as in vivo endoscopy and ex vivo histopathological analyses of tissues harvested from murine models of human colorectal cancer, demonstrate significant binding specificity to α-L-fucose of these UEA-1-FITC-MSN constructs. Lastly, we describe our use of (a) pH-sensitive MSNs, to target and controllably release the chemotherapeutic drug doxorubicin, and (b) FLIM, to dynamically monitor drug release, migration, and DNA intercalation during the early apoptosis – as a prototypical analysis of nanotheranostic function. In these studies we discovered that monitoring the rate of change of doxorubicin fluorescence lifetime within cell nuclei enables the detection of very subtle changes in chromatin structure, well in advance of the commencement of DNA fragmentation. Taken together, these studies, and the endless permutations of form/function such nanocomposites afford, provide a compelling argument for the clinical translation of multifunctional MSNs and MSN composites as cancer nanotheranostic compounds. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T16:13:40Z (GMT). No. of bitstreams: 1 ntu-102-D97223204-1.pdf: 5843700 bytes, checksum: b333012fc3e72ae47793f5bd8e0955d3 (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 中文摘要 III
ABSTRACT V LIST OF SCHEMES VIII LIST OF FIGURES IX Chapter 1: General Introduction 1 1-1 Mesoporous silica nanoparticle (MSN) 1 1-1-1. Synthesis and functionalization of MSNs 1 1-1-2. Theranostic application of MSNs 3 1-1-3. Bio-elimination of MSNs 6 1-2 Mesoporous silica nanoparticles and their organic/inorganic hybrids 8 1-2-1. Organic Hybrid Mesoporous Silica Nanoparticles 9 1-2-2. Inorganic Composite Mesoporous Silica Nanoparticles 12 1-3 Luminescence of gold 15 1-3-1. Photoluminescent gold nanorods 16 1-4 References 25 Chapter 2: Plasmonic Resonance Energy Transfer In Mesoporous Silica-Encased Gold Nanorod For Two-Photon Activated Photodynamic Therapy 34 2-1 Introduction 34 2-2 Experimental section 38 2-2-1. Materials 38 2-2-2. Synthesis of MS-GNR 38 2-2-3. Synthesis of MS-GNR -PdTPP 39 2-3-4. Singlet oxygen measurement 41 2-3-5. In vitro two-photon luminescence images and PDT effects 41 2-3-6. In vivo two-photon excited PDT effect 42 2-3-7. Transmission Electron Microscopy (TEM) 44 2-3 Results and discussion 45 2-3-1. Enhancement of the photostability of GNR by the mesoporous silica confinement 45 2-3-2. Photodynamic therapy by intra-particle plasmonic energy transfer 48 2-4 Conclusions 52 2-5 References 61 Chapter 3: Endoscopic Diagnosis Of Colorectal Cancer Using Lectin-Functionalized Mesoporous Silica Nanoparticles 68 3-1 Introduction 68 3-2 Experimental section 70 3-2-1. Synthesis of FITC-MSNs 70 3-2-2. Preparation of FITC-MSN-UEA-1/PEGylated FITC-MSN-UEA-1 70 3-3-3. Cell culture and cellular uptake 72 3-3-4. AOM/DSS colorectal cancer mice model 72 3-3-5. Ex vivo specificity of FITC-MSN-UEA1 72 3-3-6. In vitro colonoscopy 73 3-3 Results and discussion 74 3-4 Conclusions 78 3-5 References 85 Chapter 4: Probing The Dynamics Of Doxorubicin-Dna Intercalation During The Initial Activation Of Apoptosis By Fluorescence Lifetime Imaging Microscopy (FLIM) 88 4-1 Introduction 88 4-2 Experimental section 90 4-2-1 Fluorescence lifetime imaging microscopy (FLIM) 90 4-2-2 Cell culture and cell uptake 91 4-2-3 Analysis of caspase-3 activity 91 4-2-4 Detection of γ-H2AX 92 4-2-5 In vitro lifetime detection 93 4-2-6 In vitro cell lifetime detection 94 4-3 Results and discussion 95 4-4 Conclusions 102 4-5 References 111 CHAPTER 5: CONCLUSIONS AND PERSPECTIVE 116 ABBREVIATIONS 119 PUBLICATION LIST 123 | |
dc.language.iso | en | |
dc.title | 多功能中孔洞複合性奈米矽球於癌症同位診斷治療之應用 | zh_TW |
dc.title | Multifunctional Mesoporous Silica Nanocomposite Nanoparticles for Theranostic Applications | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-1 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 羅履維(Leu-Wei Lo) | |
dc.contributor.oralexamcommittee | 陳培菱(Peilin Chen),周必泰(Pi-Tai Chou),吳嘉文(Chia-Wen Wu) | |
dc.subject.keyword | 中孔洞,奈米矽球,癌症治療, | zh_TW |
dc.subject.keyword | Mesoporous Silica Nanoparticles(MSN),Nanocomposite,Theranostic,Doxorubicin,Fluorescence Lifetime Imaging Microscopy (FLIM),Gold nanorod,Photoluminescence, | en |
dc.relation.page | 125 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2013-02-07 | |
dc.contributor.author-college | 理學院 | zh_TW |
dc.contributor.author-dept | 化學研究所 | zh_TW |
顯示於系所單位: | 化學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 5.71 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。